Loading company…
RhyGaze develops gene therapy intended to restore vision in people with retinal diseases.
RhyGaze develops cone optogenetic gene therapy intended to restore vision by delivering a light-sensor gene to retinal cone cells. The company is preparing for human clinical trials and is based in Basel, Switzerland. Founded in 2024, it raised USD 86 million in Series A funding in January 2025.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in